Life-Threatening Infections
Innovation with impact
In the business of trying to save lives.
Serious, invasive and often deadly fungal infections treated in the hospital setting are becoming increasingly drug resistant.
SCYNEXIS scientists and innovators who believe in the power of science have developed a new class of antifungals with the potential to battle these difficult to treat diseases.
And we are not stopping there. We continue to work to expand the use of our innovative antifungal platform use with multiple potential future indications including the treatment and prevention of invasive candidiasis, invasive aspergillosis and other fungal infections. Our antifungal platform includes several generations of triterpenoid antifungals such as oral ibrexafungerp, the first generation compound with two approved indications, SCY-247, our second generation IV and oral compound in clinical development and other novel analogs in earlier stages of development; each of them with specific and differentiating attributes, optimal to address critical needs in the antifungal space. Having the chance to continue advancing this promising antifungal platform to its maximum potential motivates us every day.
Fighting drug-resistant, often deadly pathogens
Drug resistance is a critical problem that is present now and will very likely continue growing in years to come. For example, Candida auris causes infections with high mortality and is frequently resistant to azoles and sometimes resistant all antifungal classes approved. Other Candida species have been increasingly growing resistant to many antifungals. Aspergillus strains resistant to azoles have been reported globally, and there is an increased incidence of invasive fungal infections (IFIs) that are typically resistant to current antifungal agents. Mucormycosis is a terribly debilitating fungal infection with a high mortality rate that has shown significant antifungal resistance.
There is an urgent need for new antifungal drugs to adequately manage these challenging and deadly diseases.
As the first glucan synthase inhibitor that can be given orally, our proprietary antifungal platform of triterpenoid antifungals has the potential to address several of these needs and better position our society to successfully fight the growing threat that fungal infections pose.
Invasive Fungal Infections
Invasive fungal infections kill more than one million people in hospitals each year worldwide.
Learn MoreInvasive Candidiasis
Invasive candidiasis is a serious fungal infection caused by various Candida species and occurs most frequently in immunocompromised patients.
Learn MoreOur clinical trials
SCYNEXIS is conducting several clinical trials investigating the efficacy of ibrexafungerp against serious and drug-resistant infections.
Learn MoreOur data on invasive infections
SCYNEXIS regularly presents key infectious disease study data at top medical meetings.
Learn More